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Introduction
Cardiovascular disease (CVD) remains a major cause 
of morbidity and mortality worldwide despite falling 
incidences in most high-income countries. Guidelines 
for the primary prevention of CVD usually recommend 
the use of risk-prediction tools to target treatment for 
people above a specified threshold of predicted risk. 
There has been a progressive reduction in the risk 
threshold recommended in relation to statin prescription 
for primary prevention. In England and Wales, the 
recommended threshold for treatment changed from a 
10-year CVD risk of 20% to 10% in 2014,1 compared with 
a 7·5% threshold in current US guidelines.2 These 
reductions reflect both increasing evidence of statin 
effectiveness for primary prevention and falling prices, 
making statins more cost-effective at lower levels of 
baseline risk. However, age is the most important 
predictor of CVD risk, and thus most people will exceed 
current thresholds at some point in early older age w 
years) irrespective of other risk factors.
Risk-stratified guideline recommendations rely on 
being able to accurately predict the risk of CVD events. 
Recommended risk-prediction tools differ between 
countries, reflecting variations in CVD risk factors and 
incidence. In England and Wales, the National Institute 
for Health and Care Excellence recommends the 
QRISK2 risk-prediction tool,1 which has been externally 
validated in UK primary care datasets and found to have 
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Summary
Background Primary prevention of cardiovascular disease (CVD) is guided by risk-prediction tools, but these rarely 
account for the risk of dying from other conditions (ie, competing mortality risk). In England and Wales, the 
recommended risk-prediction tool is QRISK2, and a new version (QRISK3) has been derived and internally validated. 
We aimed to externally validate QRISK3 and to assess the effects of competing mortality risk on its predictive 
performance.
Methods For this retrospective population cohort study, we used data from the Clinical Practice Research Datalink. 
We included patients aged 25–84 years with no previous history of CVD or statin treatment who were permanently 
registered with a primary care practice, had up-to-standard data for at least 1 year, and had linkage to Hospital Episode 
Statistics discharge and Office of National Statistics mortality data. We compared the QRISK3-predicted 10-year 
CVD risk with the observed 10-year risk in the whole population and in important subgroups of age and multimorbidity. 
QRISK3 discrimination and calibration were examined with and without accounting for competing risks.
Findings Our study population included 1 484 597 women with 42 451 incident CVD events (4·9 cases per 1000 person-
years of follow-up, 95% CI 4·89–4·99), and 1 420 176 men with 53 066 incident CVD events (6·7 cases per 1000 person-
years, 6·66–6·78), with median follow-up of 5·0 years (IQR 1·9–9·2). Non-CVD death rose markedly with age 
(0·4% of women and 0·5% of men aged 25–44 years had a non-CVD death vs 20·1% of women and 19·6% of men 
aged 75–84 years). QRISK3 discrimination in the whole population was excellent (Harrell’s C-statistic 0·865 in 
women and 0·834 in men) but was poor in older age groups (<0·65 in all subgroups aged 65 years or older). Ignoring 
competing risks, QRISK3 calibration in the whole population and in younger people was excellent, but there was 
significant over-prediction in older people. Accounting for competing risks, QRISK3 systematically over-predicted 
CVD risk, particularly in older people and in those with high multimorbidity.
Interpretation QRISK3 performed well at the whole population level when ignoring competing mortality risk. The 
tool performed considerably less well in important subgroups, including older people and people with multimorbidity, 
and less well again after accounting for competing mortality risk.
Funding National Institute for Health Research.
Copyright © 2021 The Author(s). Published by Elsevier Ltd. This is an Open Access article under the CC BY-NC-ND 
4.0 license.
Articles
e353 www.thelancet.com/healthy-longevity   Vol 2   June 2021
excellent discrimination and calibration at the whole 
population level.3 QRISK3, a new version of the QRISK 
tool, which includes additional morbidities for 
prediction, has been derived and internally validated 
with the same methods  and UK primary care dataset.4 
In the QRISK3 internal validation, overall model 
discrimination was excellent, although somewhat lower 
in older people, and calibration was excellent in younger 
people and very good in older people,4 but external 
validation is required before recommending any 
prediction tool for routine use.5–7
However, there are additional concerns about risk 
prediction that are not directly addressed by conventional 
external validation. In particular, people who are more 
likely to die from non-CVD conditions might have little 
potential benefit from statins but at least some risk of 
harm from treatment.8 The issue is one of competing 
risk, which in this context arises when an individual is at 
risk of dying from conditions other than CVD. These are 
obvious at the extreme—taking a statin is clearly futile in 
someone at the very end of life. However, even smaller 
levels of competing risk can lead to systematic over-
prediction of CVD risk in people at higher risk of dying 
from another cause, including older people and those 
with multimorbidity.9,10 This is because survival analyses, 
in which data are censored, usually assume that those 
lost to follow-up have the same risk of the outcome as 
those who remain in follow-up (eg, if using the 
Kaplan-Meier estimator). This assumption is incorrect if 
someone dies of another condition (competing mortality) 
because a dead person cannot have a CVD event.11 In this 
study, we aimed to externally validate QRISK3 and to 
examine the effect of competing risk on predictive 
performance.
Methods
Data source and population
For this population cohort study, we externally validated 
QRISK3 in the UK Clinical Practice Research Datalink 
(CPRD) Gold,12,13 which does not overlap with the derivation 
dataset, although it is similar in its inclusion of linked 
primary care, hospital, and mortality data. Included patients 
were permanently registered with a primary care practice, 
contributed up-to-standard data for at least 1 year, and had 
linkage to Hospital Episode Statistics (HES) discharge data 
and Office of National Statistics (ONS) mortality data; were 
aged 25–84 years with no previous history of CVD; and had 
no history of previous statin treatment. Cohort entry was 
the latest date of Jan 1, 2004, a patient’s 25th birthday, or 
contribution of up-to-standard data for at least 1 year. Cohort 
exit was the date of a first CVD event, death, prescription of 
a statin (since the main use of the prediction model is 
to make decisions about statin initiation), deregistration 
from the primary care practice, date of the last data collection 
from the practice, or the end of the study on March 31, 2016, 
whichever came first. All outcomes and predictors were 
recorded during routine clinical care and were therefore 
recorded blind to the study hypothesis. This study was 
approved by the CPRD Independent Scientific Advisory 
Committee (protocol 16_248). 
Research in context
Evidence before this study
Guidelines for the primary prevention of cardiovascular disease 
(CVD) usually recommend risk-stratified treatment. Decisions 
to start long-term medication to prevent future CVD events are 
guided by estimation of CVD risk, with treatment offered if 
patients exceed a particular risk threshold. Recommended 
risk-prediction tools vary by country, reflecting differences in 
CVD risk factors and incidence. The recommended 
risk-prediction tool in the UK is QRISK, but there are 
two criticisms of recommended tools: first, they often do not 
predict risk well in older people and people with multimorbidity 
and second, they do not account for competing mortality risk 
(the risk of dying from non-CVD causes). We searched PubMed 
from inception to Jan 8, 2021, for observational studies in 
English examining competing mortality risks in people with 
CVD or in the context of incident CVD risk prediction using the 
search terms (cardiovascular disease[MeSH Major Topic] AND 
“competing risk” AND (“heart disease risk factors”[MESH 
Terms] OR prediction)). We found 12 relevant studies 
examining over-estimation of CVD rates during follow-up, in 
the context of incident CVD in the whole population and in 
high-risk populations, such as people with atrial fibrillation, and 
in the context of additional CVD-related events in people with 
established CVD. The degree of over-estimation of CVD varied 
with the population and is believed to be higher in older people 
for whom competing mortality risk is higher but is not usually 
accounted for by CVD risk-prediction tools.
Added value of this study
This study shows that CVD risk is systematically over-predicted 
in older people and in those with more long-term conditions 
once the competing risk of non-CVD death is accounted for. 
These findings add to the evidence that risk prediction of single 
conditions that does not account for competing risks is 
unreliable in important subgroups.
Implications of all the available evidence
CVD risk-prediction models need to be validated in older people 
and in people with high multimorbidity. Better CVD risk-
prediction models are needed to stratify people who are 
potentially eligible for primary preventive treatments. Clinicians 
should consider competing mortality risks and non-CVD life 
expectancy when discussing statin initiation for primary 
prevention in older people and in people with high 
multimorbidity.
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Outcomes
A first CVD event was defined as the earliest recording of 
any fatal or non-fatal coronary heart disease, ischaemic 
stroke, or transient ischaemic attack. Fatal CVD events 
were identified with codes from the International Classifi-
cation of Diseases, tenth version (ICD-10), recorded in 
ONS death registration. Non-fatal events were identified 
either in primary care electronic health records (using 
Read codes, the standard coding system used in UK 
clinics) or HES discharge diagnoses (ICD-10 codes). Read 
and ICD-10 codes defining outcomes were those used in 
QRISK3 derivation (appendix p 2).4
Prediction model
We implemented the published QRISK3-2017 prediction 
model (under GNU Lesser General Public Licence, 
version 3) with some differences: we chose a later cohort 
entry date (Jan 1, 2004, rather than Jan 1, 1998), we 
handled missing cholesterol values differently (if no 
values were available at baseline, QRISK3 derivation 
allowed cholesterol values from after the index date to be 
used if they were measured before any event; instead, we 
only included values recorded before the index date to 
avoid using future information in prediction), and we 
evaluated the Townsend deprivation score as the median 
of the vigintile (equal 20th) of the score for the area within 
which an individual lived, as individual values were not 
available. Predictor code sets used in this study and 
methods of data handling are detailed in the 
appendix (pp 3–12, 21–165).
Multimorbidity
For each patient at baseline, we additionally calculated 
a modified Charlson Comorbidity Index (mCCI) based 
on primary care Read codes (modified such that CVD 
could not contribute to the score, as all participants were 
CVD-free at baseline). The mCCI was not used for 
prediction but was used to stratify the population to 
examine discrimination and calibration by mCCI score 
(grouped into 0, 1, 2, and 3 or more).
Missing data
The extent and management of missing data is detailed 
in the appendix (p 14). As was done in QRISK3 derivation, 
patients with missing Townsend deprivation scores 
were excluded from the cohort, those with missing data 
on ethnicity were assumed to be White, and multiple 
imputation was used for missing body-mass index, 
total cholesterol to HDL cholesterol ratio, systolic blood 
pressure and its variability, and smoking status. Multi-
variate imputation by chained equations14 was used to 
generate five imputed datasets. We combined analyses 
of these imputed datasets using Rubin’s rules15 to give 
summary point estimates with confidence limits that 
reflected the added uncertainty associated with imputing 
missing values. As with QRISK3 derivation, morbidities 
and prescribing used for prediction were assumed to 
be absent if not recorded (morbidity and prescribing 
recording in CPRD is generally good).12,13
Statistical analysis
The study size was determined by the data available in 
CPRD, which was considered sufficient,5 and no formal 
power calculation was done.5
We calculated the 10-year risk of having a cardiovascular 
event for each patient using the published QRISK3 
equation without recalibration. The performance of the 
risk score was assessed by examining discrimination and 
calibration in the whole population and in subgroups 
defined by age group (25–44, 45–64, 65–74, and 75–84 
years) and by mCCI score.
Discrimination is the ability of the risk score to 
differentiate between patients who had the event of interest 
during the study and those who did not. We used the 
truncated version of Harrell’s C-statistic to only include 
pairs for which the earliest survival time was no later than 
10 years after entry. Where considerable censoring occurs, 
Harrell’s C-statistic might overestimate discrimination. 
Therefore, we did a sensitivity analysis using a weighted 
C-statistic accounting for the probability of censoring.16 
A C-statistic of 0·5 indicates discrimination that is no 
better than chance, whereas a C-statistic of 1 indicates 
perfect discrimination. Two additional measures of 
discrimi nation were calculated: Royston’s D-index (based 
on the prognostic separation in event-free survival between 
patients with predicted risk scores higher and lower than 
the median; higher values of Royston’s D-index indicate 
greater discrimination)17 and a related R² statistic 
estimating the explained variation in the context of 
censored survival data.18
Calibration refers to how closely the predicted and 
observed probabilities are similar at group level. This was 
assessed for equally sized groups of participants ranked 
by predicted risk. Calibration of the risk score predictions 
was assessed by plotting observed risk of CVD events 
against predicted risk. Plots were generated separately by 
sex, for all patients and for prespecified subgroups of age 
and mCCI, on the basis of summary statistics pooled 
across the imputed datasets.
The following summary statistics and their SEs were 
obtained by decile of predicted risk score and for each 
imputed dataset in turn: non-parametric measures of 
observed risk or proportions of patients with a CVD event, 
the Kaplan-Meier estimator (the conventional measure 
ignoring competing risks) and the Aalen-Johansen 
estimator (an extension to allow for competing events, 
non-CVD death in this case),19 and the mean predicted 
risk score. All models were fitted in R, version 4.0.0, and 
STATA, version 11.2.
Role of the funding source
The study funder had no role in study design, data 
collection, data analysis, data interpretation, or writing of 
the report.
See Online for appendix
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Results
Of the patients assessed aged 25–84 with linkage to HES 
and ONS, 1 650 188 were women, of whom 165 591 
(10·0%) were excluded because of data inconsistencies 
(1405 [0·1%]), previous CVD (78 032 [4·7%]), statin 
prescription (83 357 [5·1%]), or missing deprivation score 
(2797 [0·2%]); and 1 623 394 were men, of whom 203 218 
(12·5%) were excluded because of data inconsistencies 
(1815 [0·1%]), previous CVD (112 073 [6·9%]), statin 
prescription (86 656 [5·3%]), or missing deprivation 
score (2674 [0·2%]). Therefore, 1 484 597 women and 
1 420 176 men were included in this study.
Across most baseline characteristics, the study 
population and the QRISK3 internal validation cohort4 
were similar (table 1) but, in this study, the prevalence 
of treated hypertension and current smoking was 
higher and recorded family history of coronary heart 
disease was lower. Missing data in this study compared 
with that in the QRISK3 internal validation cohort was 
less frequent for ethnicity, similar for systolic blood 
pressure and body-mass index, and more frequent 
for total cholesterol to HDL cholesterol ratio, systolic 
blood pressure variability, and smoking status 
(appendix p 14).
Women Men
External validation cohort 
(n=1 484 597)
Original QRISK3 internal 
validation cohort 
(n=1 360 457)
External validation cohort 
(n=1 420 176)
Original QRISK3 internal 
validation cohort 
(n=1 310 841)
Age, years 46·0 (15·3) 43·3 (15·3) 44·8 (13·9) 42·6 (13·8)
Body-mass index 25·9 (5·7) 25·4 (5·1) 26·6 (4·7) 25·9 (4·2)
Total cholesterol to HDL cholesterol ratio 3·7 (1·1) 3·6 (1·2) 4·4 (1·3) 4·4 (1·3)
Systolic blood pressure, mm Hg 125·4 (18·0) 123·1 (18·1) 131·1 (16·2) 128·8 (16·2)
Systolic blood pressure variability 10·0 (5·7) 9·3 (6·1) 10·3 (6·2) 9·9 (6·8)
Ethnicity
White or not recorded 1 363 146 (91·8%) 1 218 391 (89·6%) 1 336 221 (94·1%) 1 171 281 (89·4%)
Indian 22 488 (1·5%) 23 146 (1·7%) 15 322 (1·1%) 26 479 (2·0%)
Pakistani 9550 (0·6%) 10 919 (0·8%) 6647 (0·5%) 14 787 (1·1%)
Bangladeshi 2594 (0·2%) 8738 (0·6%) 2145 (0·2%) 11 914 (0·9%)
Other Asian 13 697 (0·9%) 17 078 (1·3%) 9973 (0·7%) 15 966 (1·2%)
Black Caribbean 9505 (0·6%) 13 142 (1·0%) 6687 (0·5%) 10 642 (0·8%)
Black African 18 804 (1·3%) 27 678 (2·0%) 12 822 (0·9%) 25 251 (1·9%)
Chinese 6739 (0·5%) 8992 (0·7%) 3503 (0·2%) 6098 (0·5%)
Other 38 074 (2·6%) 32 373 (2·4%) 26 829 (1·9%) 28 423 (2·2%)
Smoking status (% of non-missing)
Non-smoker 707 774 (59·8%) 706 671 (51·9%) 478 671 (49·0%) 512 252 (39·1%)
Former smoker 217 404 (18·4%) 194 545 (14·3%) 216 883 (22·2%) 196 459 (15·0%)
Light smoker 85 277 (7·2%) 154 565 (11·4%) 75 260 (7·7%) 177 693 (13·6%)
Moderate smoker 111 690 (9·4%) 74 933 (5·5%) 112 411 (11·5%) 84 914 (6·5%)
Heavy smoker 62 236 (5·3%) 38 218 (2·8%) 93 457 (9·6%) 64 107 (4·9%)
Family history of CHD* 97 624 (6·6%) 164 023 (12·1%) 75 237 (5·3%) 123 039 (9·4%)
Type 1 diabetes 3752 (0·3%) 3351 (0·2%) 4843 (0·3%) 3932 (0·3%)
Type 2 diabetes 17 022 (1·1%) 15 872 (1·2%) 21 077 (1·5%) 19 318 (1·5%)
Treated hypertension 115 944 (7·8%) 77 694 (5·7%) 82 768 (5·8%) 56 920 (4·3%)
Rheumatoid arthritis 12 702 (0·9%) 15 139 (1·1%) 4724 (0·3%) 7055 (0·5%)
Atrial fibrillation 8199 (0·6%) 5229 (0·4%) 10 620 (0·7%) 6874 (0·5%)
Chronic kidney disease (stage 3, 4, or 5) 6918 (0·5%) 6949 (0·5%) 5659 (0·4%) 4232 (0·3%)
Migraine 117 692 (7·9%) 89 504 (6·6%) 41 471 (2·9%) 36 141 (2·8%)
Corticosteroid use 20 674 (1·4%) 31 775 (2·3%) 11 824 (0·8%) 18 634 (1·4%)
HIV or AIDS 289 (<0·1%) 1595 (0·1%) 445 (<0·1%) 2945 (0·2%)
Systemic lupus erythematosus 1725 (0·1%) 1349 (0·1%) 165 (<0·1%) 134 (<0·1%)
Atypical antipsychotic use 8469 (0·6%) 6268 (0·5%) 8336 (0·6%) 6597 (0·5%)
Severe mental illness 110 799 (7·5%) 94 724 (7·0%) 57 264 (4·0%) 57 830 (4·4%)
Erectile dysfunction diagnosis or treatment NA NA 39 264 (2·8%) 31 136 (2·4%)
Data are mean (SD) or n (%). CHD=coronary heart disease. NA=not applicable. *In a first-degree relative younger than 60 years.
Table 1: Baseline data in external validation cohort and in original QRISK3 internal validation cohort8
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42 451 incident cases of CVD were observed in 
women during 8 594 620 years of follow-up (4·9 cases per 
1000 person-years, 95% CI 4·89–4·99), compared with 
53 066 incident cases in men during 7 896 704 years of 
follow-up (6·7 cases per 1000 person-years, 6·66–6·78). 
CVD incidence rose progressively with age 
(appendix p 15) and was moderately lower than that 
observed in QRISK3 derivation.4 Median follow-up in the 
whole cohort was 5·0 years (IQR 1·9–9·2), with 
641 596 (22·1%) of 2 904 773 patients remaining in the 
cohort and CVD event-free at 10-year follow-up. By 
10 years, CVD events occurred in 39 048 (2·6%) of 
1 484 597 women compared with 49 146 (3·5%) of 
1 420 176 men, and non-CVD deaths occurred in 40 839 
(2·8%) women compared with 38 226 (2·7%) men 
(table 2). Censoring due to statin initiation was more 
common than that due to non-CVD death, but almost 
two thirds of both men and women were censored due to 
deregistration or to having less than 10 years of follow-up 
before the end of the study (table 2). Patterns of censoring 
were markedly different by age and by mCCI. Censoring 
due to statin initiation rapidly increased with increasing 
levels of multimorbidity and with age, peaking in the 
65–74 years age group in which approximately a quarter 
of men and women started statins for primary prevention 
during follow-up. Censoring due to deregistration or 
having less than 10 years of follow-up by the end of study 
was more common in younger, than in older, participants 
and in participants with lower multimorbidity, whereas 
censoring due to non-CVD death was more common in 
older participants and people with higher multimorbidity.
Overall discrimination was excellent and similar to 
that of QRISK3 internal validation4 (for women, Harrell’s 
C-statistic 0·865 for external validation vs 0·880 for 
internal validation, D 2·43 vs 2·49, R² 58·5% vs 59·6%; for 
men, Harrell’s C-statistic 0·834 vs 0·858, D 2·10 vs 2·26, 
R² 51·3% vs 55·0%; table 3). However, discrimination 
varied markedly within the age group and mCCI categories, 
with discrimination being best in the youngest group 
(25–44 years) and the group with lowest multimorbidity 
(mCCI 0) and worst in the oldest group (75–84 years) 
and the group with highest multimorbidity (mCCI ≥3). 
Sensitivity analysis using a censoring-adjusted C-statistic 
found a somewhat lower discrimination than in the main 
analysis, but did not alter the overall interpretation 
(appendix p 16).
Ignoring competing mortality risks, calibration was 




Non-fatal CVD CVD death Censored At least 10 years 
of follow-up
Non-CVD death Started statin Deregistered or end 
of study* before 
10 years of follow-up
All women 1 484 597 34 047 (2·3%) 5001 (0·3%) 40 839 (2·8%) 128 183 (8·6%) 926 832 (62·4%) 349 695 (23·6%)
All men 1 420 176 42 675 (3·0%) 6471 (0·5%) 38 226 (2·7%) 145 482 (10·2%) 895 421 (63·1%) 291 901 (20·6%)
Women, age (years)
25–44 813 157 3064 (0·4%) 124 (<0·1%) 3250 (0·4%) 14 076 (1·7%) 612 336 (75·3%) 180 307 (22·2%)
45–64 465 484 10 825 (2·3%) 671 (0·1%) 11 101 (2·4%) 68 552 (14·7%) 242 367 (52·1%) 131 968 (28·4%)
65–74 121 267 8958 (7·4%) 1142 (0·9%) 9454 (7·8%) 32 139 (26·5%) 43 549 (35·8%) 26 205 (21·6%)
75–84 84 689 11 200 (13·2%) 3064 (3·6%) 17 034 (20·1%) 13 416 (15·8%) 28 760 (34·0%) 11 215 (13·2%)
mCCI
0 1 187 965 21 890 (1·8%) 2908 (0·2%) 22 287 (1·9%) 86 730 (7·3%) 769 100 (64·7%) 285 050 (24·0%)
1 229 651 7981 (3·5%) 1273 (0·6%) 9272 (4·0%) 28 553 (12·4%) 128 966 (56·2%) 53 606 (23·3%)
2 51 295 2956 (5·8%) 567 (1·1%) 6211 (12·1%) 9787 (19·1%) 22 698 (44·2%) 9076 (17·7%)
≥3 15 686 1220 (7·8%) 253 (1·6%) 3069 (19·6%) 3113 (19·8%) 6068 (38·7%) 1963 (12·5%)
Men, age (years)
25–44 815 950 5659 (0·7%) 461 (0·1%) 4205 (0·5%) 25 050 (3·1%) 614 615 (75·3%) 165 960 (20·3%)
45–64 458 384 19 595 (4·3%) 2105 (0·5%) 12 211 (2·7%) 86 437 (18·9%) 234 266 (51·2%) 103 770 (22·6%)
65–74 96 404 9870 (10·2%) 1607 (1·7%) 9572 (9·9%) 26 821 (27·8%) 31 910 (33·1%) 16 624 (17·2%)
75–84 49 438 7551 (15·3%) 2298 (4·6%) 12 238 (24·8%) 7174 (14·5%) 14 630 (29·6%) 5547 (11·2%)
mCCI
0 1 173 065 30 524 (2·6%) 4269 (0·4%) 22 906 (2·0%) 104 942 (8·9%) 763 831 (65·1%) 246 593 (21·0%)
1 201 200 8228 (4·1%) 1368 (0·7%) 7903 (3·9%) 29 919 (14·9%) 113 921 (56·6%) 39 861 (19·8%)
2 34 665 2814 (8·1%) 549 (1·6%) 4758 (13·7%) 8088 (23·3%) 13 994 (40·4%) 4462 (12·9%)
≥3 11 246 1109 (9·9%) 285 (2·5%) 2659 (23·6%) 2533 (22·5%) 3675 (32·7%) 985 (8·8%)
Data are n or n (%). CVD=cardiovascular disease. mCCI=modified Charlson Comorbidity Index. *March 31, 2016.
Table 2: Follow-up and censoring events at 10 years
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women aged 25–44 years (figure 1; appendix pp 17–18). 
However, QRISK3 over-predicted CVD risk in older age 
groups. When stratifying by mCCI, we found evidence 
of some over-prediction in the group with lowest 
multimorbidity (mCCI 0) and poor calibration and 
under-prediction in patients with highest multimorbidity 
(mCCI ≥3).
When competing mortality risks were accounted for 
(figure 1), we observed over-prediction of risk at higher 
levels of predicted CVD risk in all women. The same 
pattern of increasing over-prediction with increasing 
age was observed, but in greater magnitude, and 
calibration was poor in older age groups. Although we 
observed some under-prediction of risk in patients with 
mCCI scores of 3 or higher for those at lower predicted 
CVD risk, the overall pattern was over-prediction of 
CVD risk, which increased with multimorbidity, and 
poor calibration in the highest multimorbidity groups 
(mCCI 2 and ≥3).
Ignoring competing mortality risks, calibration was 
excellent for all men, although with somewhat greater 
over-prediction at higher levels of predicted CVD risk 
than in women (figure 2; appendix pp 19–20). Calibration 
was excellent for men aged 25–44 years, but QRISK3 
progressively over-predicted CVD risk with increasing 
age. We observed evidence of some over-prediction in the 
group with lowest multi morbidity (mCCI 0) and poor 
calibration and under-prediction in the group with 
highest multimorbidity (mCCI ≥3).
When competing mortality risks were accounted 
for (figure 2), we observed over-prediction of risk at 
higher levels of predicted CVD risk in all men. Calibration 
was poor, with large over-prediction in older age groups. 
Although we observed some under-prediction of risk in 
patients with mCCI scores of 3 or higher for those at 
lower predicted CVD risk, the overall pattern was over-
prediction of CVD risk, which increased with 
multimorbidity, and poor calibration in the groups with 
highest multimorbidity (mCCI 2 and ≥3).
Discussion
This external validation study found that, at the whole 
population level, QRISK3 had excellent discrimination 
overall (the ability of the model to distinguish people 
at higher or lower risk. However, as is expected when 
examining discrimination in subsets of the modelled 
population,20 discrimination was moderate at best in older 
people and in people with high levels of multi morbidity. 
Calibration (the extent to which predicted and observed 
event rates are similar) was excellent in the whole 
population when ignoring competing mortality risks, but 
we found evidence of systematic over-prediction of 
CVD risk after competing risks were accounted for. 
Calibration was considerably worse in older people and in 
those with higher levels of multimorbidity, for whom 
QRISK3 systematically over-predicted risk, particularly 
after competing mortality risks were accounted for.
At the whole population level, QRISK3 does 
appropriately sort the whole population into groups with 
varying levels of cardiovascular risk (with some small 
over-prediction), but the model performs relatively poorly 
in older people and people with high multimorbidity, 
partly because of high competing mortality risk.
The strengths of our study include methodological con-
duct consistent with recommendations,6,21 comprehensive 
detailing of all code sets to facilitate replication, and 
explicit assessment of prediction in subgroups and 
competing mortality risks.
The limitations of this study largely reflect problems 
common to all studies using routine primary care 
data, including the original QRISK3 derivation.22 The 
prevalence of missing data for key predictors was high. 
As was done in the original QRISK3 derivation, we 
used multiple imputation for missing data but, in this 
context, the assumption that data are missing at 
random is a strong one because risk factors are 
plausibly more likely to be measured in people at 
higher risk (as observed in other studies).10  However, 
this limitation of routine data compared with research 
Women Men
Harrell’s C (95% CI) Royston’s D (95% CI) R² (95% CI) Harrell’s C (95% CI) Royston’s D (95% CI) R² (95% CI)
All patients 0·865 (0·861–0·868) 2·43 (2·41–2·45) 58·5% (58·1–58·8) 0·834 (0·831–0·837) 2·10 (2·08–2·12) 51·3% (50·8–51·7)
Age group, years
25–44 0·758 (0·747–0·769) 1·69 (1·63–1·76) 40·7% (38·8–42·5) 0·757 (0·749–0·764) 1·57 (1·52–1·61) 36·9% (35·6–38·2)
45–64 0·707 (0·702–0·713) 1·25 (1·22–1·28) 27·2% (26·1–28·3) 0·681 (0·677–0·685) 1·04 (1·02–1·07) 20·6% (19·8–21·4)
65–74 0·641 (0·635–0·647) 0·82 (0·77–0·86) 13·7% (12·4–15·1) 0·612 (0·606–0·617) 0·63 (0·59–0·66) 8·6% (7·7–9·5)
75–84 0·611 (0·605–0·616) 0·61 (0·56–0·66) 8·1% (6·9–9·3) 0·585 (0·579–0·591) 0·46 (0·42–0·51) 4·9% (4·1–5·8)
mCCI
0 0·863 (0·859–0·867) 2·40 (2·38–2·43) 57·9% (57·4–58·4) 0·827 (0·824–0·831) 2·02 (2·00–2·04) 49·4% (48·9–49·8)
1 0·846 (0·840–0·852) 2·20 (2·17–2·24) 53·6% (52·8–54·4) 0·829 (0·823–0·835) 2·00 (1·96–2·03) 48·7% (47·8–49·6)
2 0·789 (0·778–0·799) 1·73 (1·67–1·78) 41·6% (39·9–43·2) 0·728 (0·717–0·739) 1·28 (1·22–1·34) 28·1% (26·2–29·9)
≥3 0·744 (0·728–0·760) 1·40 (1·32–1·48) 31·8% (29·2–34·4) 0·695 (0·678–0·712) 1·13 (1·04–1·21) 23·2% (20·5–26·0)
mCCI=modified Charlson Comorbidity Index.
Table 3: Discrimination and model fit
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cohorts with fewer missing data is balanced by routine 
data cohorts being more representative. All recent 
QRISK models have also used Jan 1, 1998, 
as the index date (the earliest that patients can enter 
the study). Therefore, much observed follow-up in 
model derivation is historical,22 and there is a trade-off 
between using an index date in the distant past (when 
CVD incidence was higher than it presently is) or a 
more recent index date (in which case more patients 
are excluded because of previous statin use). Our choice 
of a more recent index date might partly explain why 
QRISK3 was observed to over-predict risk in our val-
idation. Deriving clinical prediction tools on 
increasingly historical data is probably biased,22 but 
using more recent data with greater rates of previous 
statin initiation might also be biased. There is clearly 
no optimal resolution to this dilemma. Finally, loss to 
follow-up before a CVD event was common, which is 
Figure 1: Calibration in women without accounting for competing risks (left) and accounting for competing risks (right)
CVD=cardiovascular disease. mCCI=modified Charlson Comorbidity Index. *Observed risk was based on the Kaplan-Meier estimator, which does not account for 
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25–44 years observed risk
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relevant to model assumptions about censored patients. 
We specifically examined the effect of censoring due to 
non-CVD death, but it is also an assumption that those 
who deregistered from practices had the same CVD risk 
as those who did not. This seems likely to be the case 
for younger people, but less so for older people, for 
whom change of address will be more commonly 
driven by change in health status (eg, moving to 
sheltered housing or a care home).
External validations of previous QRISK tools have also 
found excellent discrimination and calibration at the 
whole population level when competing mortality risks 
were ignored (ie, answering the question of what the 
risk of CVD is, assuming this person does not die of 
anything else in the following 10 years).3 Our findings 
are comparable at the whole population level (ignoring 
competing risks) but even so, calibration was poor in 
patients aged 75–84 years and only moderate in those 
Figure 2: Calibration in men without accounting for competing risks (left) and accounting for competing risks (right)
CVD=cardiovascular disease. mCCI=modified Charlson Comorbidity Index. *Observed risk was based on the Kaplan-Meier estimator, which does not account for 
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aged 65–74 years and in those with the highest levels of 
multimorbidity (mCCI ≥3).
We observed greater over-prediction at the whole 
population level once competing mortality risk was 
accounted for. Calibration was notably poorer once 
competing risk was accounted for, particularly in older 
patients and those with higher multimorbidity. These 
findings are consistent with other studies examining the 
effect of competing risks on estimated CVD risk in 
people without CVD,9,11,23,24 with established CVD,25 and 
in other contexts, including stroke risk in people with 
atrial fibrillation.26,27 QRISK2 has also been shown to 
systematically over-predict CVD risk in a contemporary 
population of people with type 2 diabetes, with 
increasingly poor discrimination with increasing age, 
highlighting that good performance at the whole 
population level does not necessarily mean good 
performance in important subgroups.20,28
At the population level, QRISK3 does segment the 
population into groups in which the observed risk of 
CVD is very similar to the predicted risk (supporting its 
use to guide risk-stratified treatment decisions). However, 
this overall assessment of prediction performance was 
largely driven by good performance in younger people 
with fewer coexisting long-term conditions. For older 
people and people with more long-term conditions, 
prediction was poor to fair, particularly when competing 
risks were accounted for. Still, even the lower degree of 
over-prediction observed in younger and less 
multimorbid groups can also sometimes change 
treatment recommendations. Similar issues probably 
apply to other CVD risk-prediction models that do not 
account for competing risk. We believe that predicting 
CVD events without accounting for risk of death 
from other causes is misleading, particularly in people 
at high risk of non-CVD death. Therefore, clinicians 
should carefully consider life expectancy related to other 
conditions when discussing long-term cardiovascular 
primary preventive treatment.
Further research would be beneficial in several areas. 
CVD causes a large proportion of deaths in many high-
income countries, which will reduce the effect of competing 
risks. Additional studies are needed to examine the effect of 
competing risk when predicting less fatal conditions, for 
which the effect on predictive performance is likely to be 
greater. It is also uncertain whether a better approach to 
CVD prediction would be to create separate models for 
important subgroups of age and multimorbidity (as is 
already done for sex), not least because the relationship 
between classic CVD risk factors and CVD might weaken 
with age. Further research is needed to evaluate the relative 
merits of omnibus versus subgroup models, and to better 
quantify the uncertainty at the individual level of risk-
prediction tools that perform well at a population level.29 A 
weakness of existing UK primary care datasets in deriving 
risk-prediction rules is the large loss to follow-up when 
there is a long time horizon for risk prediction. This study 
has examined the effect of competing risk, but loss to 
follow-up due to practice deregistration is likely to create 
over-prediction in at least some population subsets. 
External validation in large geographical populations with 
lower loss to follow-up (such as the SAIL Databank in 
Wales) would be valuable, as would larger-scale data 
federation to derive and validate new risk-prediction tools 
for comparison with QRISK3 and other prediction 
models.22 New risk prediction tools could also usefully 
include statin treatment at baseline in prediction, in the 
way that QRISK3 includes antihyper tensive treatment in 
prediction.4 Finally, the value of risk-factor treatment in 
older people with multimorbidity and co-prescribing who 
are routinely excluded from trials could be usefully clarified 
with targeted randomised controlled trials.30
In conclusion, QRISK3 performs well at the whole 
population level but systematically over-predicts CVD risk 
in older people and people with high multimorbidity. 
Clinicians should consider broader effects on life 
expectancy when discussing statin initiation for primary 
prevention in older people and people with high 
multimorbidity, in whom CVD risk is likely to be over-
predicted. Better calibrated prediction models are needed 
in these groups.
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